# China NMPA Drug Inspection - Liangshan Xinxin Traditional Chinese Medicine Pieces Co., Ltd. - Stir-fried Atractylodes lancea

Source: https://www.keypedia.com/records/china_drug_inspection/liangshan-xinxin-traditional-chinese-medicine-pieces-co-ltd/acb9b807-8a34-44a4-8a59-fa808aaedf1e
Source feed: China

> China NMPA drug inspection for Liangshan Xinxin Traditional Chinese Medicine Pieces Co., Ltd. published September 11, 2017. Drug: Stir-fried Atractylodes lancea. On September 11, 2017, the Henan Provincial Food and Drug Administration, operating under the regulatory framework of Ch

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Henan Provincial Food and Drug Administration Regarding 3 Batches of Substandard Drugs Found in Spot Checks
- Company Name: Liangshan Xinxin Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2017-09-11
- Drug Name: Stir-fried Atractylodes lancea
- Inspection Finding: Unqualified (including content, appearance, etc.)
- Action Taken: Control measures such as sealing, seizing, and suspending sales; legal action against the units that source the inspected goods.
- Summary: On September 11, 2017, the Henan Provincial Food and Drug Administration, operating under the regulatory framework of China's National Medical Products Administration (NMPA), announced that three batches of drugs from distinct manufacturers were found to be substandard. This discovery followed testing conducted by the Luoyang Municipal Food and Drug Inspection Institute of Henan Province. The companies involved were Hainan Haishen Tongzhou Pharmaceutical Co., Ltd., with substandard Spironolactone tablets (batch 1610041); Anhui Xinxing Traditional Chinese Medicine Pieces Co., Ltd., for Atractylodes lancea (batch 170103); and Yabao Pharmaceutical Sichuan Pharmaceutical Co., Ltd., for Calcium gluconate oral solution (batch 151201). The primary violations identified pertained to the content and properties of these drug batches, indicating they did not meet required quality specifications. In response, the Henan Provincial Food and Drug Administration mandated immediate actions, including the sealing, seizing, and suspension of sales for the affected drugs. Additionally, investigations were initiated to ensure legal punishment for the responsible parties, demonstrating a commitment to enforcing drug quality and patient safety standards.

Company: https://www.keypedia.com/companies/liangshan-xinxin-traditional-chinese-medicine-pieces-co-ltd/cc104fc6-8f7d-4947-8317-54eb29154916